CD274 and urothelial carcinoma: Especially, we found that the IRRS can be used as an effective predictor for predicting the effects of immunotherapy in urothelial carcinoma cohort with anti-PD-L1 treatment (IMvigor210) and malignant melanoma cohort with anti-PD-1 treatment (GSE78220).